SCHEMBL5568022

SCHEMBL5568022

CCC(C1CCCCC1)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
TSHR P16473 2/20 0.50
CYP3A4 P08684 1/20 0.50
MMP1 P03956 1/20 0.48
MMP2 P08253 1/20 0.48
MMP3 P08254 1/20 0.48
ADORA3 P0DMS8 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 1/20 0.43
KCNH2 Q12809 1/20 0.43
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
POLB P06746 2/20 0.42
TP53 P04637 3/20 0.41
LMNA P02545 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566978 0.79 ALDH1A1 (0.54) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL25091207 0.77 TP53 (0.45) ALDH1A1POLBTP53SMN1; SMN2KDM4E
SCHEMBL6825856 0.77 ALDH1A1 (0.51) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL19441740 0.77 ALDH1A1 (0.51) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL13041357 0.75 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL29952032 0.73 ALDH1A1 (0.47) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL17446911 0.72 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL20153642 0.72 ALDH1A1 (0.46) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL26343858 0.71 ALDH1A1 (0.49) ALDH1A1TSHRCYP3A4ADORA3HTT
SCHEMBL13897010 0.70 GAA (0.50) ALDH1A1CYP3A4MMP1MMP2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304064-B2 1-[(indol-3-yl)carbonyl]piperazine derivatives N.V. ORGANON (NL) 2007-12-04 US disclosed
EP-1549637-B1 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES ORGANON NV (NL) 2007-05-02 EP disclosed
US-20050250760-A1 1-[(Indol-3-yl)carbonyl]piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2005-11-10 US disclosed
EP-1549637-A1 1- (INDOL-3-YL)CARBONYL PIPERAZINE DERIVATIVES Akzo Nobel N.V. (NL) 2005-07-06 EP disclosed
WO-2004000832-A1 1-[(INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AKZO NOBEL N.V. (NL) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250760-A1 1-[(Indol-3-yl)carbonyl]piperazine derivatives IDO1, OPRL1, OPRK1 ALDH1A1 689/4885TSHR 3363/4885CYP3A4 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.